Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Non-Current Assets (2022 - 2025)

Atara Biotherapeutics' Other Non-Current Assets history spans 4 years, with the latest figure at $886000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 71.45% year-over-year to $886000.0; the TTM value through Dec 2025 reached $886000.0, down 71.45%, while the annual FY2025 figure was $886000.0, 71.45% down from the prior year.
  • Other Non-Current Assets reached $886000.0 in Q4 2025 per ATRA's latest filing, up from $881000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $51.4 million in Q1 2022 to a low of $39000.0 in Q4 2022.
  • Average Other Non-Current Assets over 4 years is $6.5 million, with a median of $3.4 million recorded in 2024.
  • The largest YoY upside for Other Non-Current Assets was 12320.51% in 2023 against a maximum downside of 86.57% in 2023.
  • A 4-year view of Other Non-Current Assets shows it stood at $39000.0 in 2022, then skyrocketed by 12320.51% to $4.8 million in 2023, then tumbled by 35.94% to $3.1 million in 2024, then tumbled by 71.45% to $886000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Other Non-Current Assets are $886000.0 (Q4 2025), $881000.0 (Q3 2025), and $927000.0 (Q2 2025).